Mioflazine hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577434

CAS#: 79467-24-6

Description: Mioflazine hydrochloride is a nucleoside transport inhibitor that acts on adenosine to improve sleep.

Chemical Structure

img
Mioflazine hydrochloride
CAS# 79467-24-6
Instruction

Theoretical Analysis

MedKoo Cat#: 577434
Name: Mioflazine hydrochloride
CAS#: 79467-24-6
Chemical Formula: C29H34Cl4F2N4O3
Exact Mass: 664.14
Molecular Weight: 666.410
Elemental Analysis: C, 52.27; H, 5.14; Cl, 21.28; F, 5.70; N, 8.41; O, 7.20

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Mioflazine hydrochloride; Mioflazine HCl; R51,469; R 51,469; R-51,469

IUPAC/Chemical Name: 1-Piperazineacetamide, 3-(aminocarbonyl)-4-(4,4-bis(4-fluorophenyl)butyl)-N-(2,6-dichlorophenyl)-, dihydrochloride, monohydrate

InChi Key: CAEGSEJNBXUDOD-UHFFFAOYSA-N

InChi Code: InChI=1S/C29H30Cl2F2N4O2.2ClH.H2O/c30-24-4-1-5-25(31)28(24)35-27(38)18-36-15-16-37(26(17-36)29(34)39)14-2-3-23(19-6-10-21(32)11-7-19)20-8-12-22(33)13-9-20;;;/h1,4-13,23,26H,2-3,14-18H2,(H2,34,39)(H,35,38);2*1H;1H2

SMILES Code: O.Cl.Cl.NC(=O)C1CN(CC(=O)Nc2c(Cl)cccc2Cl)CCN1CCCC(c3ccc(F)cc3)c4ccc(F)cc4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 666.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ijzerman AP, Thedinga KH, Custers AF, Hoos B, Van Belle H. Inhibition of nucleoside transport by a new series of compounds related to lidoflazine and mioflazine. Eur J Pharmacol. 1989 Aug 15;172(3):273-81. PubMed PMID: 2776845.

2: Flameng W, Xhonneux R, Vanhaecke J, Van de Water A, Suy M. Prevention of the "no reflow" phenomenon in the canine heart by mioflazine. Basic Res Cardiol. 1985 Jan-Feb;80(1):27-36. PubMed PMID: 3985924.

3: Griffith DA, Conant AR, Jarvis SM. Differential inhibition of nucleoside transport systems in mammalian cells by a new series of compounds related to lidoflazine and mioflazine. Biochem Pharmacol. 1990 Nov 15;40(10):2297-303. PubMed PMID: 2244931.

4: Ver Donck L, Liu GS, Vandeplassche G, Borgers M. Effects of lidoflazine and mioflazine against potassium and veratrine induced shape changes in isolated rat cardiac myocytes. Basic Res Cardiol. 1987 Jan-Feb;82(1):74-81. PubMed PMID: 3593184.

5: Wauquier A, Van Belle H, Van den Broeck WA, Janssen PA. Sleep improvement in dogs after oral administration of mioflazine, a nucleoside transport inhibitor. Psychopharmacology (Berl). 1987;91(4):434-9. PubMed PMID: 3108923.

6: Liu GS, Huang DX, Yang XS. [Preventive effect of mioflazine on myocardial calcium-overload during postischemic reperfusion in the rabbit heart]. Zhonghua Nei Ke Za Zhi. 1988 Apr;27(4):221-3, 261. Chinese. PubMed PMID: 3219938.

7: Baer HP, Serignese V, Moorji A, Van Belle H. In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters. Naunyn Schmiedebergs Arch Pharmacol. 1991 Apr;343(4):365-9. PubMed PMID: 1852220.

8: Ravens U, Liu GS, Vandeplassche G, Borgers M. Protection of human, rat, and guinea-pig atrial muscle by mioflazine, lidoflazine, and verapamil against the destructive effects of high concentrations of Ca2+. Cardiovasc Drugs Ther. 1992 Feb;6(1):47-58. PubMed PMID: 1576096.

9: Buchwald A, Ito BR, Schaper W. Influence of mioflazine on canine coronary blood flow and on adenine nucleotide and nucleoside content under normal and ischemic conditions. J Cardiovasc Pharmacol. 1987 Aug;10(2):213-21. PubMed PMID: 2441173.

10: Flameng W, Xhonneux R, Van Belle H, Borgers M, Van de Water A, Wouters L, Wijnants J, Thoné F, Van Daele P, Janssen PA. Cardioprotective effects of mioflazine during 1 h normothermic global ischaemia in the canine heart. Cardiovasc Res. 1984 Sep;18(9):528-37. PubMed PMID: 6467270.

11: Vandeplassche G, Hermans C, Borgers M, Xhonneux R, Flameng W. Beneficial effect of mioflazine in limiting myocardial infarct size in the anesthetized dog. Res Commun Chem Pathol Pharmacol. 1984 Apr;44(1):167-70. PubMed PMID: 6729248.

12: Pirovano IM, Van Belle H, Ijzerman AP. Inhibition of nucleoside uptake in human erythrocytes by a new series of compounds related to lidoflazine and mioflazine. Eur J Pharmacol. 1990 Dec 15;189(6):419-22. PubMed PMID: 2073930.

13: Hugtenburg JG, Mathy MJ, de Haan N, Beckeringh JJ, van Zwieten PA. The influence of calcium antagonists on the adenine nucleotide metabolism in the guinea-pig working heart during ischaemia and reperfusion. Naunyn Schmiedebergs Arch Pharmacol. 1991 May;343(5):496-504. PubMed PMID: 1881460.

14: Van Belle H, Xhonneux R, Flameng W, Wynants J. Oral pretreatment with mioflazine completely changes the pattern and remarkably prolongs the accumulation of nucleosides in ischemic and reperfused myocardium. Basic Res Cardiol. 1986 Jul-Aug;81(4):407-16. PubMed PMID: 3778420.

15: Baer HP, Haq A, el-Soofi A, Serignese V, Paterson AR. Potencies of mioflazine and its derivatives as inhibitors of adenosine transport in isolated erythrocytes from different species. J Pharm Pharmacol. 1990 May;42(5):367-9. PubMed PMID: 1976791.

16: Wood AJ, Isted K, Hynd J, Main MJ, Noble MI, Parker J, Drake-Holland AJ. Mioflazine, a potentially protective drug against ischaemic damage: a study in dogs. Eur Heart J. 1985 Aug;6(8):695-701. PubMed PMID: 4054139.

17: Conant AR, Jarvis SM. Nucleoside influx and efflux in guinea-pig ventricular myocytes. Inhibition by analogues of lidoflazine. Biochem Pharmacol. 1994 Aug 30;48(5):873-80. PubMed PMID: 8093099.

18: Hugtenburg JG, Van Voorst MJ, Van Marle J, Mathy MJ, Beckeringh JJ, Van Veen HA, Hendriks MG, Van Zwieten PA. The influence of nifedipine and mioflazine on mitochondrial calcium overload in normoxic and ischaemic guinea-pig hearts. Eur J Pharmacol. 1990 Mar 13;178(1):71-8. PubMed PMID: 2332029.

19: Marangos PJ, Loftus T, Wiesner J, Lowe T, Rossi E, Browne CE, Gruber HE. Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia. 1990 May-Jun;31(3):239-46. PubMed PMID: 2344840.

20: Bontemps F, Van den Berghe G, Hers HG. Pathways of adenine nucleotide catabolism in erythrocytes. J Clin Invest. 1986 Mar;77(3):824-30. PubMed PMID: 3949980; PubMed Central PMCID: PMC423468.